Evidence map›Paper›PMID 26117647›Full record

ArticleBioorganic & medicinal chemistry2015

Pentamidine analogs as inhibitors of [(3)H]MK-801 and [(3)H]ifenprodil binding to rat brain NMDA receptors.

Michael L Berger, Dorota Maciejewska, Jean Jacques Vanden Eynde, Madhusoodanan Mottamal, Jerzy Żabiński, Paweł Kaźmierczak, Mateusz Rezler, Ivana Jarak, Ivo Piantanida, Grace Karminski-Zamola and 6 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 5 countries.

Michael L BergerCenter for Brain Research, Medical University of Vienna, Vienna, Austria. Electronic address: michael.berger@meduniwien.ac.at.
Dorota MaciejewskaDepartment of Organic Chemistry, Medical University of Warsaw, Warsaw, Poland.
Jean Jacques Vanden EyndeLaboratory of Organic Chemistry, University of Mons-UMONS, Mons, Belgium.
Madhusoodanan MottamalCollege of Pharmacy, Xavier University of Louisiana, New Orleans, USA.
Jerzy ŻabińskiDepartment of Organic Chemistry, Medical University of Warsaw, Warsaw, Poland.
Paweł KaźmierczakDepartment of Organic Chemistry, Medical University of Warsaw, Warsaw, Poland.
Mateusz RezlerDepartment of Organic Chemistry, Medical University of Warsaw, Warsaw, Poland.
Ivana JarakDepartment of Organic Chemistry, University of Zagreb, Zagreb, Croatia.
Ivo PiantanidaDepartment of Organic Chemistry, University of Zagreb, Zagreb, Croatia.
Grace Karminski-ZamolaDepartment of Organic Chemistry, University of Zagreb, Zagreb, Croatia.
Annie MayenceCollege of Pharmacy, Xavier University of Louisiana, New Orleans, USA.
Patrick RebernikCenter for Brain Research, Medical University of Vienna, Vienna, Austria.
Arvind KumarDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Mohamed A IsmailDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
David W BoykinDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Tien L HuangCollege of Pharmacy, Xavier University of Louisiana, New Orleans, USA.
Medical University of Warsaw · PLGeorgia State University · USUniversity of Zagreb · HRXavier University of Louisiana · USMedical University of Vienna · ATUniversity of Mons · BE

Funding

Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
NIMHD NIH HHS 2G12MD007595NIMHD NIH HHS G12 MD007595
6 · The paper itself

Abstract

The anti-protozoal drug pentamidine is active against opportunistic Pneumocystis pneumonia, but in addition has several other biological targets, including the NMDA receptor (NR). Here we describe the inhibitory potencies of 76 pentamidine analogs at 2 binding sites of the NR, the channel binding site labeled with [(3)H]MK-801 and the [(3)H]ifenprodil binding site. Most analogs acted weaker at the ifenprodil than at the channel site. The spermine-sensitivity of NR inhibition by the majority of the compounds was reminiscent of other long-chain dicationic NR blockers. The potency of the parent compound as NR blocker was increased by modifying the heteroatoms in the bridge connecting the 2 benzamidine moieties and also by integrating the bridge into a seven-membered ring. Docking of the 45 most spermine-sensitive bisbenzamidines to a recently described acidic interface between the N-terminal domains of GluN1 and GluN2B mediating polyamine stimulation of the NR revealed the domain contributed by GluN1 as the most relevant target.

Indexed as

AnimalsBinding SitesBrainDizocilpine MaleateMolecular Docking SimulationPentamidinePiperazinePiperazinesPiperidinesProtein Structure, TertiaryRatsReceptors, N-Methyl-D-AspartateTritiumDizocilpine MaleateifenprodilPentamidinePiperazinePiperazinesPiperidinesReceptors, N-Methyl-D-AspartateTritiumAlkylationBisbenzamidineCouplingIfenprodilMolecular dockingNMDA receptorPentamidinePolyamineRadioligand bindingRat brain

Identifiers

PMID26117647
PMCPMC4910395
OpenAlexW593281469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.